NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has closed its public offering, raising $27.5 million in gross proceeds.

The firm offered 5.5 million shares at $5 per share. Aegis Capital was the sole book-running manager for the offering. Rosetta granted the underwriter a 45-day option to purchase up to 825,000 additional shares to cover any overallotments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.